ClinicalTrials.gg
CompletedNCT02053753Updated Dec 29, 2017Results posted

Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product

A Phase 1 interventional study of Denosumab CP4 and Denosumab CP2 in Healthy Volunteer, sponsored by Amgen. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-29.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
146
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To evaluate the bioequivalence based on pharmacokinetics (PK) of a single 120 mg subcutaneous dose of denosumab administered to healthy volunteers using denosumab CP4 or denosumab CP2 drug products.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • denosumab, bioequivalence
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion:

  • Healthy male and female, ages ≥ 18 to ≤ 65 years (inclusive)
  • Body weight > 60 to \< 100 kg at time of screening
  • Clinically acceptable physical exams and laboratory tests (blood hematology, blood chemistry, urinalysis) and no history or evidence of any medical disorder that would pose a risk to subject safety or interfere with study evaluations or procedures
  • Normal or clinically acceptable (ECG) (12-lead reporting heart rate and PR, QRS, , and QTc intervals) at screening
  • Willing to be confined to the research facility for 2 consecutive nights
  • Subject will be available for follow-up assessments

Exclusion Criteria:

Prior diagnosis of bone disease, or any condition that will affect bone metabolism such as, but not limited to: osteoporosis, osteogenesis imperfecta, hyperparathyroidism, hyperthyroidism, hypothyroidism, osteomalacia, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, current flare-up of osteoarthritis and/or gout, active , renal disease (defined as [GFR] \< 45 mL/min), Paget's disease of the bone, recent bone fracture (within 6 months), malabsorption syndrome

  • Presents with any psychiatric disorder, which may prevent the subject from completing the study or interfere with the interpretation of the study results
  • Significant changes in physical activity during the 6 months before study drug administration or constant levels of intense physical exercise
  • Prior use of any non-Amgen approved medications within 4 weeks or 5-half lives (whichever time period is longer) of study drug administration and for the duration of the study. This includes medications such as, but not limited to: bisphosphonates, fluoride, hormone replacement therapy (ie, estrogen) or selective estrogen receptor modulator, such as ralaxofene, calcitonin, strontium, parathyroid hormone or derivatives, supplemental vitamin D [>1000 IU/day], glucocorticosteroids, anabolic steroids, calcitriol, diuretics, over the counter medications, herbal supplements
  • Positive for (HIV) at screening or known diagnosis of acquired immune deficiency syndrome (AIDS)
  • Positive surface antigen (HepBsAg) (indicative of chronic hepatitis B) or detectable virus ribonucleic acid (RNA) by polymerase chain reaction (PCR) at screening (indicative of active hepatitis C - screening is generally done by hepatitis C antibody [HepCAb], followed by hepatitis C virus RNA by PCR if HepCAb is positive)
  • Known sensitivity to any of the products to be administered during the study
  • Prior denosumab administration
  • Receiving or has received any drug (or is currently using an investigational device) within 30 days before receiving study drug, or at least 10 times the respective elimination half-life (whichever period is longer) and for the duration of the study
  • Women with a positive pregnancy test at screening or day-1
  • Men and women of who are unwilling to practice a highly effective method of while on study through 5 months after receiving the last dose of study drug. Highly effective methods of birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with either barrier methods, hormonal birth control or intrauterine device (women)
  • Women who are lactating/breastfeeding or who plan to breastfeed while on study through 5 half-lives after receiving the dose of study drug
  • Women planning to become pregnant while on study through 5 months after receiving the dose of study drug
  • Men with partners who are pregnant or planning to become pregnant while the subject is on study through 5 months after receiving the last dose of study drug
  • Unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol is prohibited 24 hours prior to screening, 24 hours prior to check-in on day -1, and throughout confinement. Alcohol is also limited to no more than 2 drinks per day during the outpatient period of the study through completion of day 127 (EOS). A standard drink is equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine, or 1.5 ounces of 80 proof distilled spirits
  • Positive urine screen for alcohol and/or drugs with a high potential for abuse at screening or day -1. Rescreening of the subject within 48 hours of a positive result is permitted
  • Any other condition that might reduce the chance of obtaining data required by protocol or that might compromise the ability to give truly and/or comply with study procedures
  • Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal, and/or pre-existing dental disease
  • Recent tooth extraction (within 6 months of screening visit)
  • Evidence of hypocalcemia at screening
  • Known vitamin D deficiency
  • Known intolerance to calcium or vitamin D supplements
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Drug Product CP4

    Participants received a single dose of 120 mg denosumab manufactured using the new CP4 process subcutaneously on day 1.

    Drug: Denosumab CP4

  • Experimental
    Drug Product CP2

    Participants received a single dose of 120 mg denosumab manufactured using the current CP2 process subcutaneously on day 1.

    Drug: Denosumab CP2

Interventions

  • DrugDenosumab CP4

    Denosumab produced by a process referred to as CP4, administered subcutaneously.

  • Denosumab produced by a process referred to as CP2, administered subcutaneously.

    Also known as: XGEVA®

06

What researchers measure

Primary outcomes

  1. Maximum Observed Drug Concentration (Cmax) of Denosumab

    Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

    Time frame: Day 1 predose up to day 127

  2. Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab

    Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

    Time frame: Day 1 predose up to day 127

Secondary outcomes

  1. Time to Maximum Observed Concentration (Tmax) of Denosumab

    Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

    Time frame: Day 1 predose up to day 127

  2. Half-life (T1/2) of Denosumab

    Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

    Time frame: Day 1 predose up to day 127

  3. Area Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks)

    Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis. AUEC0-18 weeks was estimated using the linear-log trapezoidal method.

    Time frame: Day 1 predose up to day 127

  4. Maximum Percent Inhibition (Imax) of Serum CTX1

    Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.

    Time frame: Day 1 predose up to day 127

  5. Time to Reach Maximum Percent Inhibition (Tmax) of Serum CTX1

    Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.

    Time frame: Day 1 predose up to day 127

  6. Number of Participants With Adverse Events

    A treatment-related adverse event (TRAE) is any treatment-emergent adverse event (AE) that per investigator review has a reasonable possibility of being caused by the investigational product.

    Time frame: From the first dose of denosumab through day 126

  7. Number of Participants Who Developed Anti-denosumab Antibodies

    Time frame: Predose on day 1, and days 29, 67 and 127

07

Results

Posted Dec 29, 2017

Participant flow

This study was conducted at 2 centers in the United States.

Participant flow — Overall Study
MilestoneDenosumab CP4Denosumab CP2
Started7274
Received treatment7171
Completed6566
Not completed78
Withdrew: Withdrawal by subject24
Withdrew: Decision by sponsor11
Withdrew: Lost to follow-up43

Outcome measures

PrimaryMaximum Observed Drug Concentration (Cmax) of Denosumab

Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

Time frame:
Day 1 predose up to day 127
Reported as:
Mean · μg/mL
Maximum Observed Drug Concentration (Cmax) of Denosumab
μg/mLDenosumab CP4Denosumab CP2
Maximum Observed Drug Concentration (Cmax) of Denosumab12.7 ± 3.5311.8 ± 3.51
Statistical analysis
  • Denosumab CP4 vs Denosumab CP2 · Ratio of geometrc means (cp4:cp2): 1.084 · 90% CI 0.995 to 1.181The ratio and confidence interval of the geometric means are based on natural log scale data converted back to the original scale.
PrimaryArea Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab

Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

Time frame:
Day 1 predose up to day 127
Reported as:
Mean · day*μg/mL
Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab
day*μg/mLDenosumab CP4Denosumab CP2
Area Under the Drug Concentration-time Curve From Time 0 to 18 Weeks Post-dose (AUC0-18 Weeks) of Denosumab579 ± 190555 ± 166
Statistical analysis
  • Denosumab CP4 vs Denosumab CP2 · Ratio of geometric means (cp4:cp2): 1.028 · 90% CI 0.934 to 1.131The ratio and confidence interval of the geometric means are based on natural log scale data converted back to the original scale.
SecondaryTime to Maximum Observed Concentration (Tmax) of Denosumab

Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

Time frame:
Day 1 predose up to day 127
Reported as:
Median · days
Time to Maximum Observed Concentration (Tmax) of Denosumab
daysDenosumab CP4Denosumab CP2
Time to Maximum Observed Concentration (Tmax) of Denosumab6.9 (2.0 to 14)7.0 (3.0 to 21)
SecondaryHalf-life (T1/2) of Denosumab

Serum denosumab concentration-time data were analyzed by non-compartmental methods. Serum concentrations below the LLOQ (20.0 ng/mL) were set to 0 before data analysis.

Time frame:
Day 1 predose up to day 127
Reported as:
Mean · days
Half-life (T1/2) of Denosumab
daysDenosumab CP4Denosumab CP2
Half-life (T1/2) of Denosumab23.9 ± 10.122.4 ± 10.2
SecondaryArea Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks)

Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis. AUEC0-18 weeks was estimated using the linear-log trapezoidal method.

Time frame:
Day 1 predose up to day 127
Reported as:
Mean · day*percent inhibition
Area Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks)
day*percent inhibitionDenosumab CP4Denosumab CP2
Area Under the Serum C-telopeptide (CTX1) Percent Inhibition-Time Curve From Time 0 to 18 Weeks Post-dose (AUEC0-18 Weeks)8380 ± 20508190 ± 2250
SecondaryMaximum Percent Inhibition (Imax) of Serum CTX1

Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.

Time frame:
Day 1 predose up to day 127
Reported as:
Mean · percent inhibition
Maximum Percent Inhibition (Imax) of Serum CTX1
percent inhibitionDenosumab CP4Denosumab CP2
Maximum Percent Inhibition (Imax) of Serum CTX169.8 ± 17.070.3 ± 13.7
SecondaryTime to Reach Maximum Percent Inhibition (Tmax) of Serum CTX1

Serum CTX1 concentration-time data were analyzed by non-compartmental methods. Serum CTX1 concentrations below the LLOQ (0.0490 ng/mL) were set to 0.0490 ng/mL before data analysis.

Time frame:
Day 1 predose up to day 127
Reported as:
Median · days
Time to Reach Maximum Percent Inhibition (Tmax) of Serum CTX1
daysDenosumab CP4Denosumab CP2
Time to Reach Maximum Percent Inhibition (Tmax) of Serum CTX13.01 (0.0 to 112)3.96 (1.0 to 126)
SecondaryNumber of Participants With Adverse Events

A treatment-related adverse event (TRAE) is any treatment-emergent adverse event (AE) that per investigator review has a reasonable possibility of being caused by the investigational product.

Time frame:
From the first dose of denosumab through day 126
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsDenosumab CP4Denosumab CP2
Any adverse event2624
Serious adverse events01
AEs leading to discontinuation of denosumab00
Fatal adverse events00
Treatment-related adverse events (TRAEs)46
Treatment-related serious adverse events00
TRAEs leading to discontinuation of denosumab00
Treatment-related fatal adverse events00
SecondaryNumber of Participants Who Developed Anti-denosumab Antibodies
Time frame:
Predose on day 1, and days 29, 67 and 127
Reported as:
Number · participants
Number of Participants Who Developed Anti-denosumab Antibodies
participantsDenosumab CP4Denosumab CP2
Number of Participants Who Developed Anti-denosumab Antibodies00

Adverse events

Collected over From the first dose of denosumab through day 126. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab CP4—0/71 (0%)26/71 (36.6%)
Denosumab CP2—1/71 (1.4%)24/71 (33.8%)
Most frequent serious events
Most frequent serious events
EventDenosumab CP4Denosumab CP2
Abscess limbInfections and infestations0/711/71
Most frequent other events
Showing 10 of 56
Most frequent other events
EventDenosumab CP4Denosumab CP2
HeadacheNervous system disorders6/714/71
NauseaGastrointestinal disorders3/710/71
Upper respiratory tract infectionInfections and infestations2/712/71
ExcoriationInjury, poisoning and procedural complications0/712/71
Blood calcium decreasedInvestigations2/712/71
Blood phosphorus decreasedInvestigations1/712/71
Back painMusculoskeletal and connective tissue disorders1/712/71
GoitreEndocrine disorders0/711/71
Eye pruritusEye disorders1/710/71
Scleral discolourationEye disorders1/710/71

Baseline characteristics

The Safety Analysis Set defined as all participants who were enrolled and received denosumab.

Age, Continuous
Age, Continuous(years)Denosumab CP4Denosumab CP2Total
Mean38.9 ± 10.937.6 ± 11.338.3 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab CP4Denosumab CP2Total
Female293362
Male423880
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Denosumab CP4Denosumab CP2Total
Asian549
Black (or African American)242448
Multiple314
White394281
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Denosumab CP4Denosumab CP2Total
Hispanic/Latino202343
Not Hispanic/Latino514899
08

Study locations

2 sites
  • Research Site
    Cypress, California 90630, United States
  • Research Site
    San Antonio, Texas 78209, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2017, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2014
First posted
Feb 4, 2014
Start
Feb 2014
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Dec 29, 2017
Last update
Dec 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02053753
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 4, 2014
Start date
Feb 2014
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Dec 29, 2017
Last update
Dec 29, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion